Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier.
64 out-patients suffering from recurrent UTI were treated under double-blind conditions with one capsule daily of either the biological response modifier OM-8930 or the placebo for 3 months, followed by a 3-month observation period. Dysuria, bacteriuria, leucocyturia and antibiotic or chemotherapeutic consumption showed a significant reduction under OM-8930 in comparison with the placebo. As to the tolerance, a single case of allergic exanthema on the neck was observed in the OM-8930 group. Both the curative efficacy in the acute crisis and the consolidative efficacy in preventing further recurrences showed a highly significant superior effect of OM-8930 with respect to the placebo.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014552:Urinary Tract Infections / Q000628:therapy*
D000276:Adjuvants, Immunologic